Raman spectra and neural learning distinguish three melanoma cell lines
Source check: Source checked. Not independent scientific confirmation.
Finding: A neural classifier distinguished Raman spectra from three melanoma cell lines carrying different BRAF or NRAS variants, including a rare BRAF variant. The study collected 50 spectra per line and reported 96.7% accuracy with five-fold spectral cross-validation. This is an in-vitro cell-line measurement, with feature-selection and spectrum-level evaluation caveats; it does not demonstrate independent patient diagnosis or establish that genotype caused the spectral differences.
Technology: Artificial neural network; principal-component features
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- A feed-forward neural network learns nonlinear boundaries from principal-component Raman features to discriminate the measured cell lines.
- Test and result
- New Raman measurements from three melanoma cell lines, with neural and linear-discriminant spectral classification.
- Limitation / still unknown
- Independent cultures, patient-level diagnosis and causal assignment of spectral differences to genotype remain unestablished.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.1002/jbio.202000365
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary relevant Methods/results/limitations and exact front/canonical identity; current primary PubMed linked correction/retraction metadata checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.